Evolution of the New Decade of China Biopharma: Investing in the Future and Thinking Globally (White Paper)
August 19, 2021
Evolution of the New Decade of China Biopharma:Investing in the Future and Thinking Globally|
James T. Lee, PhD, Principal, Oncology Lead
Cello Health BioConsulting
The recent Chinese biopharma boom has been driven by six main factors: 1)Abundance of capital (government subsidies/funding, private funding, publicmarkets); 2) Traditional generics industry being de-emphasized (4+7 scheme tocentralize generic drug procurement and pricing); 3) High unmet need in keytherapeutic areas (oncology/infectious diseases/inflammatory diseases); 4) Western-trained returnees (so-called “sea turtles”); 5) Significant investment in R&D movingaway from licensing life cycle management commercial rights (generics/APIs); 6)Regulatory alignment with global standards (speed up regulatory decision-making atNational Medical Products Administration or NMPA, joining International Council forHarmonization of Technical Requirements for Pharmaceuticals for Human Use orICH, and more recently Center for Drug Evaluation drafting a guidance for conductingoncology drug trials requiring standard of care as part of control arms)…..More by clicking the Download pdf green button above.